Magic Bullets to Nanomedicine Targeted Drug Delivery System
Abstract
Nanomedicine, an advanced form of Paul Ehrlich’s "magic bullet" concept, enables targeted drug delivery to specific body sites, minimizing systemic toxicity and improving therapeutic efficacy. Various nanocarriers, including colloidal, polymer-based, and cellular systems, facilitate precise drug administration. This approach is particularly beneficial in treating cancer, neurological disorders, and cardiovascular diseases by enhancing therapeutic outcomes and reducing off-target effects. Despite its promise, nanomedicine faces challenges due to its complexity and limited understanding of its interactions with biological systems. Regulatory hurdles, lack of standardized evaluation procedures, and high healthcare costs further hinder its widespread adoption. The development of nano similar remains difficult due to challenges in assessing their equivalence to original nanomedicines. Advancements such as nanosponges offer innovative solutions by enabling controlled drug release and improved solubility. These microscopic carriers enhance medication stability and bioavailability, addressing key limitations in targeted delivery systems. The field continues to evolve, balancing technological advancements with regulatory and practical considerations.
Keywords:
Targeted drug delivery, Magic bullet, Carriers, NanoparticlesDOI
https://doi.org/10.70604/learnint.v2i1.50References
1. Mohammad Z, Zeeshan A, Faisal S, Md Wasim H, Suhail A, Sahar I, Mohd S, Nazma K. Vesicular drug delivery system used for liver diseases. World Journal of Pharmaceutical Sciences. 2017 Mar 29:28-35.
2. Fahmy TM, Fong PM, Goyal A, Saltzman WM. Targeted for drug delivery. Materials Today. 2005 Aug 1;8(8):18-26.
https://doi.org/10.1016/S1369-7021(05)71033-6
3. Benyettou F, Motte L. Nanomedicine: towards the “magic bullet” science. J Bioanal Biomed. 2016;8(2).
http://dx.doi.org/10.4172/1948-593X.1000e137
4. Valent, P., Groner, B., Schumacher, U., Superti-Furga, G., Busslinger, M., Kralovics, R., & Sörgel, F. (2016). Paul Ehrlich (1854-1915) and his contributions to the foundation and birth of translational medicine. Journal of innate immunity, 8(2), 111-120.
https://doi.org/10.1159/000443526
5. Hwisa NT, Gindi S, Rao CB, Katakam P, Rao Chandu B. Evaluation of Antiulcer Activity of Picrasma Quassioides Bennett Aqueous Extract in Rodents. Vedic Res. Int. Phytomedicine. 2013;1:27.
https://scielo.isciii.es/pdf/dyn/v31n2/03.pdf
6. Barz M. Complexity and simplification in the development of nanomedicines. Nanomedicine. 2015 Oct 1;10(20):3093-7.
https://doi.org/10.2217/nnm.15.146
7. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. Journal of controlled release. 2011 Aug 10;153(3):198-205.
https://doi.org/10.1016/j.jconrel.2011.06.001.
8. Rani, K., & Paliwal, S. (2014). A review on targeted drug delivery: Its entire focus on advanced therapeutics and diagnostics. Sch. J. App. Med. Sci, 2(1C), 328-31.
https://doi.org/10.36347/sjmcr.2025.v13i02.003
9. Nama S, Chandu BR, Awen BZ, Khagga M. Development and validation of a new RP-HPLC method for the determination of aprepitant in solid dosage forms. Tropical Journal of Pharmaceutical Research. 2011;10(4):491-7.http://dx.doi.org/10.13040/IJPSR.0975-8232.6(2).830-34
10. Adler‐Moore, J. P., & Proffitt, R. T. (2008). Amphotericin B lipid preparations: what are the differences?. Clinical Microbiology and Infection, 14, 25-36.
https://doi.org/10.1111/j. 1469-0691.2008.01979.x
11. de Vlieger JS, Borchard G, Shah VP, Flühmann B, Neervannan S, Mühlebach S. Is the EU ready for non-biological complex drug products?. GaBI J. 2016 Jan 1;3:101-2.
https://doi.org/10.5639/gabij.2016.0503.026.
12. Kiranmai M, Renuka P, Brahmaiah B, Chandu BR. Vitamin D as a promising anticancer agent.
https://doi.org/10.1586/14737140.2014.883922
13. Ehmann, F., & Pita, R. (2016). The EU is ready for non-biological complex medicinal products. GaBI J, 5, 30-35.
https://doi.org/10.5639/gabij.2016.0501.008
14. Gindi S, Methra T, Chandu BR, Boyina R, Dasari V. Antiurolithiatic and invitro anti-oxidant activity of leaves of Ageratum conyzoides in rat. World J. Pharm. Pharm. Sci. 2013 Feb 8;2:636-49.
https://doi.org/10.1016/j.apsb.2015.07.003
15. Fang RH, Hu CM, Zhang L. Nanoparticles disguised as red blood cells to evade the immune system. Expert opinion on biological therapy. 2012 Apr 1;12(4):385-9.
https://doi.org/10.1517/14712598.2012.66171
16. Gindi S, Methra T, Chandu BR, Boyina R, Dasari V. Antiurolithiatic and invitro anti-oxidant activity of leaves of Ageratum conyzoides in rat. World J. Pharm. Pharm. Sci. 2013 Feb 8;2:636-49.
https://www.researchgate.net/profile/Revathi-Boyina/publication/251566463
17. Meyer, R. A., Sunshine, J. C., & Green, J. J. (2015). Biomimetic particles as therapeutics. Trends in biotechnology, 33(9), 514-524.
https://doi.org/10.1016/j.tibtech.2015.07.001
18. Hu CM, Fang RH, Luk BT, Zhang L. Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies. Nanoscale. 2014;6(1):65-75.
https://doi.org/10.1039/C3NR05444F
19. Antonelli A, Sfara C, Rahmer J, Gleich B, Borgert J, Magnani M. Red blood cells as carriers in magnetic particle imaging. Biomedizinische Technik/Biomedical Engineering. 2013 Dec 1;58(6):517-25.
https://doi.org/10.1515/bmt-2012-0065
20. Krishnamurthy S, Gnanasammandhan MK, Xie C, Huang K, Cui MY, Chan JM. Monocyte cell membrane-derived nanoghosts for targeted cancer therapy. Nanoscale. 2016;8(13):6981-5.
Published
Abstract Display: 19 
PDF Downloads: 32 How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Deprecated: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated in /home/lapinjournals/domains/lapinjournals.com/public_html/plugins/generic/citations/CitationsPlugin.php on line 68
.